Pharma Exclusives Pressreleases
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
Tuesday, June 10, 2025RenaissThera Private Limited RenaissThera a Bengalurubased biotechnology company announced a major milestone in its obesity drug discovery program targeting the glucosedependent insulinotropic polypeptide receptor
Osteolabs GmbH and labor team w ag Announce Sales Partnership for Switzerland and Liechtenstein
Tuesday, June 10, 2025Osteolabs GmbH a German biotech company specializing in innovative diagnostic solutions for calciumrelated metabolic disorders and labor team one of the leading medical laboratories in Switzerland are pleased to announce a new strategic partnership
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes
Thursday, June 05, 2025Results of the Phase II study CONFIDENCE demonstrate that simultaneous initiation of finerenone and an SGLTinhibitor SGLTi led to significant reductions in urine albumintocreatinine ratio UACR versus either agent alone in patients with chronic kidney...
U.S. FDA approves third indication of Bayer blockbuster Nubeqa™ (darolutamide) for patients with advanced prostate cancer
Wednesday, June 04, 2025Bayer announced today that the US Food and Drug Administration FDA has approved its oral androgen receptor inhibitor ARi Nubeqa darolutamide in combination with androgen deprivation therapy ADT for use in patients with metastatic castrationsensitive...
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Wednesday, June 04, 2025Rocheannounced today that the European Commission EC has approved a label extension for Evrysdi risdiplam to include a new roomtemperature stable tablet for people living with spinal muscular atrophy SMA
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Tuesday, June 03, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announced the submission of a Marketing Authorization Application MAA to the European Medicines
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate
Tuesday, June 03, 2025BioNTech SEand Bristol Myers Squibb today announced that the companies have entered into an agreement for the global codevelopment and cocommercialization of BioNTechs investigational bispecific antibody BNT
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Tuesday, June 03, 2025Roche announced today positive results from the Phase III IMforte study of Tecentriq atezolizumab in combination with lurbinectedin Zepzelca as a firstline maintenance treatment for people with extensivestage
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Saturday, May 31, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA today announced results from a study of treatment patterns among patients with tardive dyskinesia TD residing
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Friday, May 30, 2025Roche announced today new week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis RMS maintained no disability progression and low levels of disease activity for up to two years
